Computer-aided detection (CAD) software developer iCAD has received a CE Mark in Europe for its customized artificial intelligence (AI) breast cancer risk estimation tool. The product was unveiled on the opening day of ECR 2020 Online, which runs from 15 to 19 July.
ProFound AI Risk is the first clinical support tool that provides an accurate two-year breast cancer risk estimation based on a screening mammogram, according to the vendor. It uses a range of risk factors, including age, breast density, and subtle mammographic features to assess short-term risk for breast cancer.
